Therefore, restoring endogenous p53 functions by the disruption of p53-MDM2/X interaction using non-peptide small molecule inhibitors [45,46] or peptide [47–49] currently plays one of the most promising strategies for anti-cancer drug design and development. Here, MDM2 is linked to cancer.